AbbVie Submits BLA Seeking FDA Accelerated Approval of Teliso-V for c-Met-Overexpressing Non-Small Cell Lung Cancer

Gelonghui September 29 | Biopharmaceutical company AbbVie Inc. said on Friday that it has applied to the U.S. Food and Drug Administration (FDA) for accelerated approval of its antibody-drug conjugate for certain lung cancer patients. The company noted that the application covers telisotuzumab vedotin, or teliso-V, for the treatment of adult patients with previously treated, locally advanced or metastatic epidermal growth factor receptor (EGFR) wild-type, non-squamous non-small cell lung cancer who exhibit overexpression of the c-Met protein.